Synthesis of novel pyrimido[4,5‐b]quinolines as potential anticancer agents and HER2 inhibitors

Abstract

AbstractA series of N‐arylpyrimido[4,5‐b]quinolines 3a–e and 2‐aryl‐2,3‐dihydropyrimido[4,5‐b]quinoline‐4(1H)‐ones 5a–e was designed and synthesized as potential anticancer agents against breast cancer. Compounds 3e, 5a, 5b, 5d, and 5e showed promising activity against the MCF‐7 cell line. Among them, compound 5b was the most active with IC50 of 1.67 μM. Compound 5b promoted apoptosis and induced cell cycle arrest at S phase. 5b increased the level of pro‐apoptotic proteins p53, Bax, and caspase‐7 and inhibited the anti‐apoptotic protein Bcl‐2. Furthermore, all the synthesized compounds were docked into the crystal structure of HER2 (PBD: 3 pp0). Compounds 3e, 5a, 5b, 5d, and 5e showed good energy scores and binding modes. Finally, Compound 5b was evaluated on the HER2 assay and revealed good inhibition with IC50 of 0.073 μM.